Hepatitis C (HCV) screening, diagnosis, and monitoring
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage criteria for Hepatitis C (HCV) screening, diagnostic testing (including genotype and RNA/NAT), and monitoring of viral load for initiation and follow-up of therapy for Blue Cross Blue Shield - Tennessee members.
No material clinical or coverage changes in this revision.
Coverage Criteria for HCV Testing and Monitoring
Covered Indications and Monitoring
Covered when any of the following indications are present (policy uses a combination of one-time and ongoing risk criteria):
Populations recommended for HCV testing
Covered testing populations per cited guidelines (examples consolidated by source):
USPSTF B recommendation
CDC: antibody testing followed by NAT for positives
AASLD-IDSA recommendations
WHO guidance
Initial and acute diagnostic testing
Diagnostic testing sequence per AASLD-IDSA:
Class I, Level A
Class I, Level C
Monitoring for patients undergoing or after DAA therapy
Laboratory monitoring recommendations from AASLD-IDSA and AGA:
Class I, Level C/A
SVR12 confirms cure
AGA/AASLD guidance
HCV in pregnancy
Testing and monitoring in pregnancy per AASLD-IDSA:
AASLD-IDSA Rating IIb/I
Rating I, B
Liver disease severity assessment
Recommended methods to assess fibrosis/cirrhosis:
AASLD-IDSA/EASL guidance
Screening, Diagnosis, and Referral Criteria
Covered when following guideline-recommended screening and diagnostic steps:
Screening
- Populations: Includes adults ≥18 at least once (IHS) and all pregnant persons during each pregnancy (IHS); some organizations recommend targeted rather than universal screening in low-risk adults—follow applicable local/government guidance.
Confirmed HCV RNA indicates active infection and warrants referral for DAA therapy
EASL: genotype useful; resistance testing not recommended
Coverage for hepatitis C testing and related services is dependent on the member's specific benefit plan at the time of the request. Providers should verify the member's plan benefits and applicable Medicare/Medicaid specifications before ordering tests. Requests for testing that fall outside the covered indications described in this policy (for example, tests not meeting the one-time testing criteria for adults >18 years or not aligned with listed risk/exposure groups) may be denied.
The AASLD advises not to repeat hepatitis C viral load testing outside of antiviral therapy, noting that repeat virologic testing when patients are not receiving antiviral treatment generally does not change clinical management. For monitoring related to therapy, quantitative HCV RNA testing is recommended prior to initiating direct-acting antiviral (DAA) therapy and at defined intervals during and after treatment to document response and sustained virologic response (SVR). Providers should follow guideline-recommended timing for RNA testing when initiating or assessing antiviral therapy rather than ordering serial viral load tests in untreated individuals.
Not all guideline bodies recommend universal screening for low-risk adults. The Canadian Task Force on Preventive Health Care (CTFPHC) recommends against screening adults who are not at elevated risk for HCV. Similarly, the Society of Obstetricians and Gynecologists of Canada (SOGC) does not recommend universal screening for individuals capable of becoming pregnant; instead, SOGC recommends targeted testing for those who fall into defined at‑risk categories after counselling and informed consent.
Provider Actions, Documentation, and Testing Requirements
Genotype and HCV RNA testing (coverage & timing)
Genotype and quantitative HCV RNA (viral load) testing are required to guide treatment selection, document baseline viremia, and monitor response to direct-acting antiviral (DAA) therapy. A single HCV genotype test (one-time) should be performed prior to initiating therapy when results may alter regimen, dosing, or duration. Quantitative HCV RNA testing is required prior to starting therapy to document baseline viral load, during therapy (per guideline timing), at end of treatment, and post-treatment to document sustained virologic response (SVR).
- One-time HCV genotype testing prior to initiation of DAA therapy when clinically relevant.
- Quantitative HCV RNA (NAT/NAAT) prior to therapy, at week 4 on therapy, at end of treatment, and at 12 weeks post-treatment (SVR12); consider 24-week testing when indicated.
- For acute infection, perform quantitative HCV RNA every 4–8 weeks for 6–12 months to evaluate spontaneous clearance versus persistence.
Coverage dependent on benefit
Coverage and payment for testing are subject to the member's specific benefit plan. Requests for testing that fall outside of the member's covered benefits, or that are inconsistent with the indications and timing described in this policy and cited guidance, may be denied.
- Verify member benefits prior to ordering tests.
- Testing inconsistent with benefits or outside specified indications may be denied.
Government policy precedence
When federal or state government coverage determinations (for example, Medicare Local Coverage Determinations or National Coverage Determinations) conflict with this policy, the applicable government policy takes precedence and will be applied for members covered by those programs.
- Check LCDs, NCDs, and state Medicaid rules for members covered under those programs.
- Government coverage policy supersedes internal policy where conflicts exist.
Genotype directs regimen
HCV genotype and subtype influence selection of antiviral regimen, dosing, and duration. Document genotype results in the medical record prior to prescribing non-pangenotypic DAAs and use genotype information to select the most appropriate therapy.
- Perform genotype/subtype testing when results may alter treatment choice, especially if prescribing a non-pangenotypic DAA.
- Document genotype in records used for treatment authorization and dispensing.
Monitoring viral load
Use quantitative HCV RNA testing to document baseline viral load and to monitor on-treatment response and post-treatment cure (SVR). Adhere to guideline-recommended timepoints to assess virologic response and to support medical necessity for ongoing or additional testing.
- Obtain a quantitative HCV RNA prior to initiation of antiviral therapy (baseline).
- Repeat quantitative HCV RNA at ~4 weeks on therapy (on-treatment monitoring), at end of treatment, and at 12 weeks after completion to document SVR (SVR12). Consider 24-week post-treatment testing in select cases per clinician judgment or guideline suggestions.
- For patients with ongoing risk factors, consider periodic HCV RNA testing after SVR to detect reinfection.
Genotype and resistance testing guidance
EASL advises that genotype/subtype testing is useful where available and does not limit access to care, but routine pre-treatment resistance testing is not recommended. Clinicians should follow current guideline statements (EASL, AASLD-IDSA, WHO) regarding when genotype or resistance testing may be appropriate.
- Determine genotype/subtype when it may influence regimen selection and when testing availability does not impede access to treatment.
- Do not routinely perform pre-treatment HCV resistance testing unless indicated by specific clinical circumstances or as recommended by current guidance (eg, prior DAA failure or when resistance data would change management).
- Follow specialty society guidance and local lab capabilities when considering testing for resistance-associated substitutions.
Definitions and Key Terms
Background and Context
Hepatitis C virus (HCV) is a blood-borne, positive-stranded RNA virus that can establish chronic infection and lead to progressive liver disease, including cirrhosis and hepatocellular carcinoma. Many infected individuals are asymptomatic, which contributes to underdiagnosis. HCV exists as multiple genotypes (commonly numbered 1–6), and genotype influences regimen selection because antiviral efficacy, dosing, and duration can vary by genotype. Diagnostic evaluation typically begins with serologic anti-HCV screening followed by nucleic acid testing (quantitative HCV RNA by PCR) to confirm active infection and to establish baseline viremia for treatment planning and monitoring.
Policy Revision History
Policy adopted (Avalon policy recommendation) and became effective on 2023-07-01.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.